VIDEO: Aflibercept 8 mg continues to show good results in DME through 2 years

ByDiana Do, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Diana V. Do, MD, FASRS, discusses 2-year data from the PHOTON clinical trial investigating aflibercept 8 mg for the treatment of diabetic macular edema.

According to Do, aflibercept 8 mg demonstrated noninferiority to aflibercept 2 mg in visual acuity outcomes when dosed at either 12 weeks or 16 weeks, which was sustained through 2 years of treatment.

“I think 8 mg of aflibercept will be a future treatment option for our patients, and that will give them even more durable VEGF suppression,” Do said.

Published by:

Sources/Disclosures

Collapse

Source:

Do DV. Aflibercept 8 mg for diabetic macular edema: 2-year results from the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.

Disclosures: Do reports having financial disclosures for Boehringer Ingelheim, Genentech, Kodiak Sciences, Kriya and Regeneron.

American Society of Retina Specialists Meeting

Read more

VIDEO: Aflibercept 8 mg continues to show good results in DME through 2 years

Related Content